These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24054151)

  • 1. Localization and expression of VMAT2 aross mammalian species: a translational guide for its visualization and targeting in health and disease.
    Schafer MK; Weihe E; Eiden LE
    Adv Pharmacol; 2013; 68():319-34. PubMed ID: 24054151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reserpine- and tetrabenazine-sensitive transport of (3)H-histamine by the neuronal isoform of the vesicular monoamine transporter.
    Erickson JD; Eiden LE; Schafer MK; Weihe E
    J Mol Neurosci; 1995; 6(4):277-87. PubMed ID: 8860238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.
    Erickson JD; Schafer MK; Bonner TI; Eiden LE; Weihe E
    Proc Natl Acad Sci U S A; 1996 May; 93(10):5166-71. PubMed ID: 8643547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vesicular amine transporter expression and isoform selection in developing brain, peripheral nervous system and gut.
    Schütz B; Schäfer MK; Eiden LE; Weihe E
    Brain Res Dev Brain Res; 1998 Mar; 106(1-2):181-204. PubMed ID: 9555003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individual residues contribute to multiple differences in ligand recognition between vesicular monoamine transporters 1 and 2.
    Finn JP; Edwards RH
    J Biol Chem; 1997 Jun; 272(26):16301-7. PubMed ID: 9195934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of two vesicular monoamine transporters.
    Peter D; Liu Y; Sternini C; de Giorgio R; Brecha N; Edwards RH
    J Neurosci; 1995 Sep; 15(9):6179-88. PubMed ID: 7666200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors.
    Anlauf M; Eissele R; Schäfer MK; Eiden LE; Arnold R; Pauser U; Klöppel G; Weihe E
    J Histochem Cytochem; 2003 Aug; 51(8):1027-40. PubMed ID: 12871984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat.
    Weihe E; Schäfer MK; Erickson JD; Eiden LE
    J Mol Neurosci; 1994; 5(3):149-64. PubMed ID: 7654518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport.
    Bernstein AI; Stout KA; Miller GW
    J Neurosci Methods; 2012 Aug; 209(2):357-66. PubMed ID: 22698664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.
    Temple W; Mendelsohn L; Kim GE; Nekritz E; Gustafson WC; Lin L; Giacomini K; Naranjo A; Van Ryn C; Yanik GA; Kreissman SG; Hogarty M; Matthay KK; DuBois SG
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):474-481. PubMed ID: 26338179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of gastrin processing by vesicular monoamine transporter type 1 (VMAT1) in rat gastrin cells.
    Hussain I; Bate GW; Henry J; Djali P; Dimaline R; Dockray GJ; Varro A
    J Physiol; 1999 Jun; 517 ( Pt 2)(Pt 2):495-505. PubMed ID: 10332097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine.
    Raffo A; Hancock K; Polito T; Xie Y; Andan G; Witkowski P; Hardy M; Barba P; Ferrara C; Maffei A; Freeby M; Goland R; Leibel RL; Sweet IR; Harris PE
    J Endocrinol; 2008 Jul; 198(1):41-9. PubMed ID: 18577569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Species-specific vesicular monoamine transporter 2 (VMAT2) expression in mammalian pancreatic beta cells: implications for optimising radioligand-based human beta cell mass (BCM) imaging in animal models.
    Schäfer MK; Hartwig NR; Kalmbach N; Klietz M; Anlauf M; Eiden LE; Weihe E
    Diabetologia; 2013 May; 56(5):1047-56. PubMed ID: 23404442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of vesicular monoamine transporter (VMAT) 1 and 2 in gastrointestinal endocrine tumours.
    Jakobsen AM; Andersson P; Saglik G; Andersson E; Kölby L; Erickson JD; Forssell-Aronsson E; Wängberg B; Ahlman H; Nilsson O
    J Pathol; 2001 Nov; 195(4):463-72. PubMed ID: 11745679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cloning and functional expression of a tetrabenazine sensitive vesicular monoamine transporter from bovine chromaffin granules.
    Howell M; Shirvan A; Stern-Bach Y; Steiner-Mordoch S; Strasser JE; Dean GE; Schuldiner S
    FEBS Lett; 1994 Jan; 338(1):16-22. PubMed ID: 8307150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine.
    Ugolev Y; Segal T; Yaffe D; Gros Y; Schuldiner S
    J Biol Chem; 2013 Nov; 288(45):32160-32171. PubMed ID: 24062308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action.
    Huang M; He W; Rajagopal L; Kudwa A; Grigoriadis DE; Meltzer HY
    Pharmacol Biochem Behav; 2020 Mar; 190():172872. PubMed ID: 32084491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple residues contribute independently to differences in ligand recognition between vesicular monoamine transporters 1 and 2.
    Finn JP; Edwards RH
    J Biol Chem; 1998 Feb; 273(7):3943-7. PubMed ID: 9461580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
    Stahl SM
    CNS Spectr; 2018 Aug; 23(4):239-247. PubMed ID: 30160230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.
    Horton DB; Nickell JR; Zheng G; Crooks PA; Dwoskin LP
    J Neurochem; 2013 Oct; 127(2):177-86. PubMed ID: 23875622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.